Clinical Trial Update: Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

View source ↗

Summary

Expanded access study of TAS-102 (trifluridine/tipiracil) in metastatic colorectal cancer, noting the drug is approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Colorectal Cancer Metastatic | Status: APPROVED_FOR_MARKETING